TY - JOUR T1 - Machine learning applied to atopic dermatitis transcriptome reveals distinct therapy-dependent modification of the keratinocyte immunophenotype JF - medRxiv DO - 10.1101/2019.12.14.19014977 SP - 2019.12.14.19014977 AU - K. Clayton AU - A. Vallejo AU - S. Sirvent AU - J. Davies AU - G. Porter AU - F. Lim AU - M.R. Ardern-Jones AU - M.E. Polak Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/12/19/2019.12.14.19014977.abstract N2 - Background Atopic dermatitis (AD) arises from a complex interaction between an impaired epidermal barrier, environmental exposures, and the infiltration of Th1/Th2/Th17/Th22 T cells. Transcriptomic analysis has advanced understanding of gene expression in cells and tissues. However, molecular quantitation of cytokine transcripts does not predict the importance of a specific pathway in AD or cellular responses to different inflammatory stimuli.Objective To understand changes in keratinocyte transcriptomic programmes in human cutaneous disease during development of inflammation and in response to treatment.Methods We performed in silico deconvolution of the whole-skin transcriptome. Using co-expression clustering and machine learning tools, we resolved the gene expression of bulk skin (n=7 datasets, n=406 samples), firstly, into unsupervised keratinocyte immune response phenotypes and, secondly, into 19 cutaneous cell signatures of purified populations from publicly available datasets.Results We identify three unique transcriptomic programmes in keratinocytes, KC1, KC2, KC17, characteristic to immune signalling from disease-associated helper T cells. We cross-validate those signatures across different skin inflammatory conditions and disease stages and demonstrate that the keratinocyte response during treatment is therapy dependent. Broad spectrum treatment with ciclosporin ameliorated the KC17 response in AD lesions to a non-lesional immunophenotype, without altering KC2. Conversely, the specific anti-Th2 therapy, dupilumab, reversed the KC2 immunophenotype.Conclusion Our analysis of transcriptomic signatures in cutaneous disease biopsies reveals the complexity of keratinocyte programming in skin inflammation and suggests that the perturbation of a single axis of immune signal alone may be insufficient to resolve keratinocyte immunophenotype abnormalities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWellcome Trust Sir Henry Dale FellowshipAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data available through GEOADAtopic dermatitisAD-AcLLesional (acute) AD skinAD-ChLLesional (chronic) AD skinAD-LesLesional (acute or chronic) AD skinAD-NonNon-lesional AD skinCD4Cluster of differentiation 4CD8Cluster of differentiation 8DDCCD11c+ Dermal Dendritic CellFDRFalse Discovery RateGCRMAGene Chip Robust Multiarray AveragingGOGene OntologyGOBPGene Ontology, Biological ProcessHHHealthyIFNInterferonIL-1Interleukin-1IL-13Interleukin-13IL-17Interleukin-17IL-22Interleukin-22IL-26Interleukin-26IL-4Interleukin-4IL4RαInterleukin-4 Receptor, alpha subunitKCKeratinocytesKC1Keratinocyte transcriptomic programme to type 1 inflammationKC17Keratinocyte transcriptomic programme to type 17 inflammationKC2Keratinocyte transcriptomic programme to type 2 inflammationKC22Keratinocyte transcriptomic programme to type 22 inflammationKFGKeratinocyte Growth FactorKRT6AKeratin 6A geneKRT6BKeratin 6B geneLCLangerhans CellLIMMALinear Models for Microarray DataMCLMarkov Clustering algorithmPs-LesLesional psoriatic skinPs-NonNon-lesional psoriatic skinS100S100 protein family geneSCORADSCORing AD indexSCORAD5050% improvement in baseline SCORAD indexSERPINSerine protease inhibitor family geneTh1Type 1 inflammationTh17Type 17 inflammationTh2Type 2 inflammationTh22Type 22 inflammationTNFTumour Necrosis Factor ER -